Skip Navigation

European Heart Journal 1994 15(5):641-647;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by BRZOSTEK, T.
Right arrow Articles by DE GEEST, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BRZOSTEK, T.
Right arrow Articles by DE GEEST, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Early and late exercise capacity after acute myocardial infarction treated with recombinant tissue-plasminogen activator

T. BRZOSTEK*, F. VAN DE WERF, L. MORTELMANS{dagger}, I. SCHEYS{ddagger}, E. LESAFFRE{ddagger}, J. S. DUBIEL* and H. DE GEEST

*Institute of Cardiology Krakow, Poland
{dagger}Department of Cardiology, UZ Gasthuisberg, Leuven Belgium
{ddagger}Nuclear Medicine and Medical Statistics, UZ Gasthuisberg, Leuven Belgium

Received 10 August 1993; revised 7 December 1993; .

Correspondence: Hilaire De Geest, MD, Department of Cardiology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.

Abstract

Thrombolytic therapy salvages jeopardized myocardium and preserves left ventricular function. Therefore, a beneficial effect on exercise tolerance and haemodynamic adaptation to exercise can be anticipated. In the present study the results of bicycle exercise tests, performed at 10 to 14 days and at more than 1 year after infarction, were compared between patients randomized double blindly to recombinant tissue plasminogen activator (rt-PA) or placebo. At 2 weeks, the maximal heart rate (140 vs 130 beats. min–1 P=0.017), systolic blood pressure (169 vs 161 mmHg, P=0.018) and pressure-rate product (22907 vs 20865 beats. min-1mmHg, P=0.0025) were higher in rt-PA treated patients (n=145) than in controls (n=142). At a mean follow-up of 16 months, rt-PA patients (n=126) performed a higher total and peak work load (733 vs 600 Watts. min, P=0.027 and 133 vs 100 Watts, P=-0.036, respectively) than control patients (n=122). During both exercise tests the incidence of clinical or electrocardiographic signs of ischaemia was similar. Multiple regression analysis indicated that age and end-systolic volume were predictors of peak pressure-rate product at 2 weeks (R2=0.11, P=0.0001). Age, sex and left ventricular ejection fraction at discharge were independent predictors of peak work load at 2 weeks (R2=0.32, P=0.0001) and the square root of peak work load at 16 months (R2=0.39, P=0.001). These findings suggest that an improved left ventricular function in the thrombolysis group plays a role in the better exercise capacity observed in rt-PA treated patients.

Key Words: Exercise test • thrombolysis • recombinant tissue plasminogen activator • myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.